Waite Laura H, Phan Yvonne L, Spinler Sarah A
1 University of the Sciences, Philadelphia, PA, USA.
Ann Pharmacother. 2017 Oct;51(10):914-920. doi: 10.1177/1060028017714003. Epub 2017 Jun 19.
In 2016, the American College of Cardiology released a decision pathway, based on expert consensus, to guide use of non-statin agents in the management of atherosclerotic cardiovascular disease risk. The purpose of this article is to assist practitioners, health systems and managed care entities with interpreting this consensus statement in order to simplify implementation of the recommendations into patient care.
Major themes from the consensus statement are briefly summarized and explained. Drug therapy recommendations are condensed into a single algorithm, while tables correlate each recommended regimen with the appropriate patient population from both a patient-level and systems-level perspective. Finally, a patient case with evidence-based decision support is explored.
These tools allow practitioners to make appropriate patient-specific decisions about the use of non-statin pharmacotherapy and enable health systems and managed care entities to more readily identify guideline-appropriate use of these agents upon review of patient profiles or prescribing patterns.
This article provides resources for healthcare providers that facilitate uptake of these recommendations into clinical practice.
2016年，美国心脏病学会发布了一条基于专家共识的决策路径，以指导非他汀类药物在动脉粥样硬化性心血管疾病风险管理中的应用。本文旨在帮助从业者、医疗系统和管理式医疗实体解读这一共识声明，以便将建议简化应用于患者护理。
简要总结并解释了共识声明的主要主题。药物治疗建议被浓缩成一个单一的算法，同时表格从患者层面和系统层面的角度将每种推荐方案与合适的患者群体相关联。最后，探讨了一个具有循证决策支持的患者案例。
这些工具使从业者能够针对患者使用非他汀类药物治疗做出适当的特定决策，并使医疗系统和管理式医疗实体在审查患者资料或处方模式时更容易识别这些药物的指南适用情况。
本文为医疗保健提供者提供了资源，有助于将这些建议纳入临床实践。
